Ren F - Search Results

1

Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer.

Wang Y, Wang C, Liu T, Qi H, Chen S, Cai X, Zhang M, Aliper A, Ren F, Ding X, Zhavoronkov A. Wang Y, et al. Among authors: ren f. J Med Chem. 2024 Jan 11;67(1):420-432. doi: 10.1021/acs.jmedchem.3c01476. Epub 2023 Dec 26. J Med Chem. 2024. PMID: 38146659

2

Discovery of thiadiazole amides as potent, S1P₃-sparing agonists of sphingosine-1-phosphate 1 (S1P₁) receptor.

Xu H, Zhang H, Luan L, Xu Y, Li C, Wang Y, Han F, Yang T, Ren F, Xiang JN, Elliott JD, Zhao Y, Guo TB, Lu H, Zhang W, Hirst D, Lindon M, Lin X. Xu H, et al. Among authors: ren f. Bioorg Med Chem Lett. 2012 Apr 1;22(7):2456-9. doi: 10.1016/j.bmcl.2012.02.016. Epub 2012 Feb 15. Bioorg Med Chem Lett. 2012. PMID: 22386243

3

Indole-propionic acid derivatives as potent, S1P3-sparing and EAE efficacious sphingosine-1-phosphate 1 (S1P1) receptor agonists.

Meng Q, Zhao B, Xu Q, Xu X, Deng G, Li C, Luan L, Ren F, Wang H, Xu H, Xu Y, Zhang H, Xiang JN, Elliott JD, Guo TB, Zhao Y, Zhang W, Lu H, Lin X. Meng Q, et al. Among authors: ren f. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2794-7. doi: 10.1016/j.bmcl.2012.02.083. Epub 2012 Mar 3. Bioorg Med Chem Lett. 2012. PMID: 22429468

4

Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).

Ren F, Deng G, Wang H, Luan L, Meng Q, Xu Q, Xu H, Xu X, Zhang H, Zhao B, Li C, Guo TB, Yang J, Zhang W, Zhao Y, Jia Q, Lu H, Xiang JN, Elliott JD, Lin X. Ren F, et al. J Med Chem. 2012 May 10;55(9):4286-96. doi: 10.1021/jm2016107. Epub 2012 Apr 20. J Med Chem. 2012. PMID: 22500954

5

Novel complex crystal structure of prolyl hydroxylase domain-containing protein 2 (PHD2): 2,8-Diazaspiro[4.5]decan-1-ones as potent, orally bioavailable PHD2 inhibitors.

Deng G, Zhao B, Ma Y, Xu Q, Wang H, Yang L, Zhang Q, Guo TB, Zhang W, Jiao Y, Cai X, Zhang J, Liu H, Guan X, Lu H, Xiang J, Elliott JD, Lin X, Ren F. Deng G, et al. Among authors: ren f. Bioorg Med Chem. 2013 Nov 1;21(21):6349-58. doi: 10.1016/j.bmc.2013.08.046. Epub 2013 Sep 3. Bioorg Med Chem. 2013. PMID: 24055079

6

2-Aminopyrimidin-4(1H)-one as the novel bioisostere of urea: discovery of novel and potent CXCR2 antagonists.

Lu H, Yang T, Xu Z, Wren PB, Zhang Y, Cai X, Patel M, Dong K, Zhang Q, Zhang W, Guan X, Xiang J, Elliott JD, Lin X, Ren F. Lu H, et al. Among authors: ren f. Bioorg Med Chem Lett. 2014 Dec 1;24(23):5493-6. doi: 10.1016/j.bmcl.2014.10.003. Epub 2014 Oct 12. Bioorg Med Chem Lett. 2014. PMID: 25455491

7

Discovery of Biaryl Amides as Potent, Orally Bioavailable, and CNS Penetrant RORγt Inhibitors.

Wang Y, Cai W, Cheng Y, Yang T, Liu Q, Zhang G, Meng Q, Han F, Huang Y, Zhou L, Xiang Z, Zhao YG, Xu Y, Cheng Z, Lu S, Wu Q, Xiang JN, Elliott JD, Leung S, Ren F, Lin X. Wang Y, et al. Among authors: ren f. ACS Med Chem Lett. 2015 May 26;6(7):787-92. doi: 10.1021/acsmedchemlett.5b00122. eCollection 2015 Jul 9. ACS Med Chem Lett. 2015. PMID: 26191367 Free PMC article.

8

Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.

Ding X, Dai X, Long K, Peng C, Andreotti D, Bamborough P, Eatherton AJ, Edge C, Jandu KS, Nichols PL, Philps OJ, Stasi LP, Wan Z, Xiang JN, Dong K, Dossang P, Ho MH, Li Y, Mensah L, Guan X, Reith AD, Ren F. Ding X, et al. Among authors: ren f. Bioorg Med Chem Lett. 2017 Sep 1;27(17):4034-4038. doi: 10.1016/j.bmcl.2017.07.052. Epub 2017 Jul 21. Bioorg Med Chem Lett. 2017. PMID: 28774425

9

Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.

Lu H, Yang T, Xu Z, Lin X, Ding Q, Zhang Y, Cai X, Dong K, Gong S, Zhang W, Patel M, Copley RCB, Xiang J, Guan X, Wren P, Ren F. Lu H, et al. Among authors: ren f. J Med Chem. 2018 Mar 22;61(6):2518-2532. doi: 10.1021/acs.jmedchem.7b01854. Epub 2018 Feb 28. J Med Chem. 2018. PMID: 29406702

10

Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.

Ding X, Stasi LP, Ho MH, Zhao B, Wang H, Long K, Xu Q, Sang Y, Sun C, Hu H, Yu H, Wan Z, Wang L, Edge C, Liu Q, Li Y, Dong K, Guan X, Tattersall FD, Reith AD, Ren F. Ding X, et al. Among authors: ren f. Bioorg Med Chem Lett. 2018 May 15;28(9):1615-1620. doi: 10.1016/j.bmcl.2018.03.045. Epub 2018 Mar 19. Bioorg Med Chem Lett. 2018. PMID: 29588215

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,952 results

Search Page

Filters